CoChat

Metformin use and improved response to therapy in esophageal adenocarcinoma

Open access
Skinner, Heath D., McCurdy, Matthew R., Echeverria, Alfredo E., Lin, Steven H., Welsh, James W., O'Reilly, Michael S., Hofstetter, Wayne L., Ajani, Jaffer A., Komaki, Ritsuko, Cox, James D., Sandulache, Vlad C., Myers, Jeffrey N., Guerrero, Thomas M. · 2013 · Acta Oncologica
Cited by 112

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We investigated the radiographic and pathologic response rate of esophageal adenocarcinoma treated with neoadjuvant chemoradiation in patients taking metformin. MATERIAL AND METHODS: Two hundred eighty-five patients with esophageal adenocarcinoma treated with concurrent chemoradiation (CRT) followed by esophagectomy from 1997 to 2012 were included in the study, including 29 diabetics taking metformin, 21 diabetics not taking metformin and 235 non-diabetics. Pre- and post-treatment positron emission tomography (PET) scans were available for 204 patients. Pathologic response was graded at the time of surgery. Response rates were compared using both the χ(2) statistic as well as ANOVA with post-hoc LSD analysis. Multivariate logistic regression analysis was performed to control for predictors of pathologic complete response (CR) after CRT. RESULTS: The overall rate of pathologic CR for the study population was 20%. The pathologic CR rate was higher in patients taking metformin (34.5%), compared to diabetic patients not taking metformin (4.8%, p = 0.01) and non-diabetic patients (19.6%, p = 0.05). Pathologic CR was related to metformin dose, with ≥ 1500 mg/d associated with a higher CR rate. No significant difference seen in pre-CRT maximum tumor SUV (p = 0.93), however post-CRT maximum SUV was significantly decreased in patients taking metformin (p = 0.05). On multivariate logistic regression, metformin use was independently associated with pathologic CR (p = 0.04). Metformin use was also associated with decreased in field loco-regional failure following radiation (p = 0.05). CONCLUSION: Metformin use is associated with a dose-dependent increased response to CRT in esophageal cancer and may be a sensitizer to this therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/0284186x.2012.718096

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 112

Metadata

Authors
Skinner, H. D., McCurdy, M. R., Echeverria, A. E., Lin, S. H., Welsh, J. W., O'Reilly, M. S., Hofstetter, W. L., Ajani, J. A., Komaki, R., Cox, J. D., Sandulache, V. C., Myers, J. N., & Guerrero, T. M.
Venue
Acta Oncologica
Published
2012-09-05
Volume
52
Issue
5
Pages
1002-1009
ISSN
  • 0284-186X (ISSN-L)
  • 1651-226X
OpenAlex
W2017407100
Cited by
112
References
3
FWCI
10.22
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin use and improved response to therapy in esophageal adenocarcinoma. https://app.cochat.ai/papers/10.3109/0284186x.2012.718096
The paper
Skinner, H. D., McCurdy, M. R., Echeverria, A. E., Lin, S. H., Welsh, J. W., O'Reilly, M. S., Hofstetter, W. L., Ajani, J. A., Komaki, R., Cox, J. D., Sandulache, V. C., Myers, J. N., & Guerrero, T. M. (2013). Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncologica. https://doi.org/10.3109/0284186x.2012.718096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.